β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

Nature Medicine

Volumn 4, Issue 7, 1998, Pages 822-826

  Soto, Claudio ^a   Sigurdsson, Einar M ^a   Morelli, Laura ^b   Kumar, R Asok ^a   Castaño, Eduardo M ^a,b   Frangione, Blas ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; BETA SHEET BREAKER PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; MALE; NEUROBLASTOMA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0031873102     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0798-822     Document Type: Article

References (30)

1. Soto, C., Branes, M.C., Alvarez, J. & Inestrosa, N.C. Structural determinants of the Alzheimer's amyloid beta-peptide. J. Neurochem. 63, 1191-1198 (1994).
2. Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G. & Cotman, C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687 (1993).
3. Lorenzo, A. & Yankner, B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA. 91, 12243-12247 (1994).
4. Yankner, B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16, 921-932 (1996).
5. Soto, C., Kindy, M.S., Baumann, M. & Frangione, B. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 226, 672-680 (1996).
6. Soto, C., Castaño, E.M., Frangione, B. & Inestrosa, N.C. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 270, 3063-3067 (1995).
7. Hilsich, C., Kisters-Woike, B., Reed, J., Masters, C.L. & Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J. Mol. Biol. 228, 460-473 (1992).
8. Lee, J.P. et al. H-1 NMR of A-beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry 34, 5191-5200 (1995).
9. Wood, J.D., Wetzel, R., Martin, J.D. & Hurle, M.R. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide /A4. Biochemistry 34, 724-730 (1995).
10. Chou, P.Y. & Fasman, G.D. Empirical predictions of protein conformation. Ann. Rev. Biochem. 47, 251-276 (1978).
11. Soto, C., Castaño, E. M., Prelli, F., Kumar, R. A. & Baumann, M. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. FEBS Letters 371, 110-114 (1995).
12. Wood, S. J., Maleeff, B., Hart, T. & Wetzel, R. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide AP. J. Mol. Biol. 256, 870-877 (1996).
13. Simmons, L.K. et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45, 373-379 (1994).
14. Sigurdsson, E.M., Lorens, S.A., Hejna, M.J., Dong, X.W. & Lee, J.M. Local and distant histopathological effects of unilateral amyloid-25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17, 893-901 (1996).
15. Sigurdsson, E.M., Lee, J.M., Dong, X.W., Hejna, M.J. & Lorens, S.A. Bilateral injections of Amyloid-β 25-35 into the amygdala of young fischer rats: Behavioral, neurochemical and time dependent histopathological effects. Neurobiol. Aging 18, 591-608 (1997).
16. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. & Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639 (1992).
17. Jimenez-Huete, A. et al. Antibodies directed to the carboxyl terminus of amyloid beta peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain. Alzheimer's Report 1, 1-7 (1998).
18. Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid precursor protein. Nature 373, 523-527 (1995).
19. Hsiao, K.K. et al. Correlative memory deficits, A elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
20. Holcomb, L. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97-100 (1998).
21. Glenner, G.G. Amyloid deposits and amyloidosis. The β-fibrilloses. N. Engl. J. Med. 302, 1283-1292 (1980).
22. Lorenzo, A., Razzaboni, B., Weir, G.C. & Yankner, B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-760 (1994).
23. Forloni, G. et al. Neurotoxicity of a prion protein fragment. Nature 362, 543-546 (1993).
24. Esler, W.P. et al. Aβ deposition inhibitor screen using synthetic amyloid. Nature Biotechnol. 15, 258-263 (1997).
25. Wisniewski, T., Ghiso, J. & Frangione, B. Alzheimer's disease and soluble Aβ. Neurobiol. Aging. 15, 143-152 (1994).
26. Thomas, P.J., Qu, B. & Pedersen, P.L. Defective protein folding as a basis of human disease. Trends Biochem. Sci. 20, 456-459 (1995).
27. Kelly, J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17 (1996).
28. Soto, C., et al. Reversal of disease-specific prion protein conformation and protease-resistance by peptides designed as β-sheet breakers. (Manuscript submitted).
29. Janossy, G., Greaves, M.F., Doenhoff, M.J. & Snajder, J. Lymphocyte activation. Quantitation of the proliferative response to mitogens using defined T and B cell populations. Clin. Exp. Immunol. 14, 581 (1973).
30. Duke CR, et al. in Current Protocols in Immunology (eds. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., and Strober, W) 17.1-17.33 (John Wiley & Sons, New York, 1995).